MUVON Therapeutics Clears Phase 2 Interim Milestone and Will Participate in the 2025 J.P. Morgan Healthcare Conference
PRESS RELEASE
Zurich, Switzerland, January 9, 2025 – MUVON Therapeutics AG, an innovative clinical-stage biotechnology company, will attend the 43rd annual J.P. Morgan Healthcare conference to highlight plans advancing its lead program.
MUVON Therapeutics, an award-winning, clinical-stage biotechnology company focused on developing a novel platform for the regeneration of skeletal muscle tissue targeting Stress Urinary Incontinence which affects over 200 million women globally, today announced it has recently received interim data from its ongoing phase 2 clinical study and will participate in the 2025 J.P. Morgan Healthcare Conference.
The interim readout of the SUISSE MPC2 study (NCT05534269) assessing the safety and efficacy of MUVON’s Muscle Precursor Cell (MPC)-based therapy in Stress Urinary Incontinence included evaluable data from 10 female patients with at least 6-months follow-up post injection of the tissue engineered product into the urethral sphincter muscle. On the basis of the interim data, the international Data Safety Monitoring Board recommended study continuation, putting the company on track for the release of the final data from the completed phase 2 study in Q3 2025.
“We’re delighted to be invited to participate in the J.P. Morgan Annual Healthcare Conference which coincides with an important inflection point as we make steady progress toward addressing the high unmet medical need in patients with stress urinary incontinence,” said Deana Mohr, Chief Executive Officer at MUVON Therapeutics. “We’re looking forward to discussing our future development plans with interested investor audiences and partners as the company is expecting to meet its capitalization objectives in Q1 of this year.”
For more information, please contact:
Dr. Deana Mohr, CEO
About MUVON Therapeutics AG
Founded in 2020, MUVON Therapeutics is a clinical-stage life science spin-off from the University of Zurich currently being accelerated by the Wyss Zurich Translational Center. MUVON Therapeutics is dedicated to the discovery and development of personalized regenerative treatments with the goal of establishing them as an affordable standard of care, with an initial focus on the treatment of stress urinary incontinence in women. Our mission is to help the millions of patients suffering from serious debilitating diseases regain control of their lives by offering them minimally invasive treatment for regeneration of skeletal muscle tissue. For more information about MUVON Therapeutics, please visit: www.muvon-therapeutics.com
